Public Market Listing
9926 HKEX
HKEX primary exchange listing
External market data link · No third-party exchange redistribution
Assets (12 total) 12 Total Assets
1 Approved
6 Phase 3 / Filed
5 Phase 1–2 / Early
14 Diseases
Disease: All diseases (12) Non-Small Cell Lung Cancer (6) Hepatocellular Carcinoma (2) Psoriasis (2) Atopic Dermatitis (2) Nasopharyngeal Carcinoma (1) Cervical Cancer (1) Atherosclerotic Cardiovascular Disease (1) Mixed Hyperlipidemia (1) Biliary Tract Cancer (1) Colorectal Cancer (1) Asthma (1) Chronic Spontaneous Urticaria (1) Prurigo Nodularis (1) Acute Myeloid Leukemia (1)
Stage: All stages (12) Approved / Phase 4 (1) Phase 3 / Filed (6) Phase 2 Phase 1 / Preclinical
Quick filter: All (12) Non-Small Cell Lung Cancer (6) Hepatocellular Carcinoma (2) Psoriasis (2) Atopic Dermatitis (2) Nasopharyngeal Carcinoma (1)
Showing 12 of 12 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Approved PD-1 Monoclonal antibody
Non-Small Cell Lung Cancer Hepatocellular Carcinoma Nasopharyngeal Carcinoma
Phase 3 PD-1×CTLA-4 Multispecific antibody
Non-Small Cell Lung Cancer Cervical Cancer Hepatocellular Carcinoma
Phase 3 IL-12/23 p40 Monoclonal antibody
Phase 3 PCSK9 Monoclonal antibody
Atherosclerotic Cardiovascular Disease Mixed Hyperlipidemia
Phase 3 IL-17A Monoclonal antibody
Phase 3 PD-1 + VEGFA Multispecific antibody
Non-Small Cell Lung Cancer Biliary Tract Cancer Colorectal Cancer
Metastatic Colorectal Cancer Phase 3 IL-4R-alpha Monoclonal antibody
Phase 2 IL-4 receptor alpha / ST2 Multispecific antibody
Atopic Dermatitis Asthma Chronic Spontaneous Urticaria Prurigo Nodularis
Phase 2 TROP2 / Nectin-4 (dual) Antibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1/2 PD-1 x LAG-3 Multispecific antibody
Non-Small Cell Lung Cancer
Phase 1/2 HER3 Antibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1/2 CD47 Monoclonal antibody
Upcoming events (43 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (9) November 2026 (2) Cadonilimab Phase 3 Gastric and Gastroesophageal Junction Adenocarcinoma Est. primary completion 2026-11 ·
NCT06341335 ·
CT.gov ↗ What to watch
Cadonilimab Phase 2 HCC, Hepatocellular Carcinoma Est. primary completion 2026-11-30 ·
NCT06984718 ·
CT.gov ↗ What to watch
December 2026 (7) Ivonescimab Phase 1/2 Solid Tumor, Adult Est. primary completion 2026-12 ·
NCT05689853 ·
CT.gov ↗ What to watch
AK129 Phase 1/2 Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma, Advanced Solid Tumors Est. primary completion 2026-12 ·
NCT06943820 ·
CT.gov ↗ What to watch
Ivonescimab Phase 3 Triple-Negative Breast Cancer (TNBC) Est. primary completion 2026-12 ·
NCT06767527 ·
CT.gov ↗ What to watch
Est. primary completion 2026-12-27 ·
NCT07436221 ·
CT.gov ↗ What to watch
Ivonescimab + Ligufalimab Phase 2 Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer Est. primary completion 2026-12-30 ·
NCT05227664 ·
CT.gov ↗ What to watch
2027 (19) January 2027 (2) Ivonescimab Phase 3 Colorectal Adenocarcinoma Est. primary completion 2027-01-13 ·
NCT06951503 ·
CT.gov ↗ What to watch
February 2027 (1) Ivonescimab Phase 1/2 Colorectal Cancer With Hepatic Metastases Est. primary completion 2027-02-28 ·
NCT07357220 ·
CT.gov ↗ What to watch
April 2027 (2) Cadonilimab Phase 1/2 Advanced Solid Tumor Est. primary completion 2027-04 ·
NCT05142423 ·
CT.gov ↗ What to watch
AK139 Phase 2 Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Est. primary completion 2027-04-30 ·
NCT07755371 ·
CT.gov ↗ What to watch
May 2027 (4) Ivonescimab Phase 1/2 Biliary Tract Cancer Est. primary completion 2027-05 ·
NCT06938321 ·
CT.gov ↗ What to watch
Ivonescimab Phase 3 Non-Small Cell Lung Cancer Est. primary completion 2027-05 ·
NCT06928389 ·
CT.gov ↗ What to watch
July 2027 (1) Manfidokimab Phase 3 Atopic Dermatitis Est. primary completion 2027-07-10 ·
NCT06767540 ·
CT.gov ↗ What to watch
August 2027 (3) AK139 Phase 2 Prurigo Nodularis (PN) Est. primary completion 2027-08 ·
NCT07883213 ·
CT.gov ↗ What to watch
Ivonescimab Phase 2 Pancreatic Cancer Est. primary completion 2027-08 ·
NCT07114315 ·
CT.gov ↗ What to watch
Ivonescimab + AK146D1 Phase 2 Advanced Non Small Cell Lung Cancer (NSCLC) Est. primary completion 2027-08-30 ·
NCT07669779 ·
CT.gov ↗ What to watch
September 2027 (1) October 2027 (1) Ivonescimab Phase 2 Platinum-sensitive Ovarian Cancer Est. primary completion 2027-10 ·
NCT06686030 ·
CT.gov ↗ What to watch
November 2027 (3) AK129 + Ligufalimab Phase 1/2 Classic Hodgkin Lymphoma Est. primary completion 2027-11 ·
NCT06642792 ·
CT.gov ↗ What to watch
AK139 Phase 2 Moderate-to-Severe Atopic Dermatitis Est. primary completion 2027-11 ·
NCT07502222 ·
CT.gov ↗ What to watch
Cadonilimab Phase 3 Gastric / Gastroesophageal Junction Adenocarcinoma Est. primary completion 2027-11-17 ·
NCT07449780 ·
CT.gov ↗ What to watch
December 2027 (1) 2028 (8) April 2028 (1) Ivonescimab Phase 3 Non-Small Cell Lung Cancer Est. primary completion 2028-04 ·
NCT06767514 ·
CT.gov ↗ What to watch
May 2028 (1) Ivonescimab Phase 3 Metastatic Colorectal Cancer (CRC) Est. primary completion 2028-05-31 ·
NCT07228832 ·
CT.gov ↗ What to watch
June 2028 (2) August 2028 (1) September 2028 (1) Ivonescimab Phase 2 Non-Small Cell Lung Cancer Est. primary completion 2028-09 ·
NCT07158840 ·
CT.gov ↗ What to watch
December 2028 (2) Ivonescimab Phase 3 Non-Small Cell Lung Cancer Est. primary completion 2028-12-31 ·
NCT05899608 ·
CT.gov ↗ What to watch
Ivonescimab Phase 3 Small Cell Lung Cancer Est. primary completion 2028-12-31 ·
NCT07010263 ·
CT.gov ↗ What to watch
2029 (4) January 2029 (1) AK139 Phase 2 Chronic Spontaneous Urticaria Est. primary completion 2029-01-08 ·
NCT07875426 ·
CT.gov ↗ What to watch
April 2029 (1) Ivonescimab Phase 2 Renal Cell Carcinoma, Clear Cell Est. primary completion 2029-04-12 ·
NCT07877194 ·
CT.gov ↗ What to watch
July 2029 (1) Cadonilimab Phase 3 Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma Est. primary completion 2029-07 ·
NCT07023315 ·
CT.gov ↗ What to watch
August 2029 (1) Cadonilimab Phase 3 Gastric / Gastroesophageal Junction Adenocarcinoma Est. primary completion 2029-08-18 ·
NCT07700979 ·
CT.gov ↗ What to watch
2030 (3) March 2030 (1) Cadonilimab Phase 2 Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma Est. primary completion 2030-03 ·
NCT07263919 ·
CT.gov ↗ What to watch
June 2030 (1) Cadonilimab Phase 3 Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer Est. primary completion 2030-06-15 ·
NCT07412613 ·
CT.gov ↗ What to watch
October 2030 (1) Ivonescimab Phase 2/3 Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC) Est. primary completion 2030-10-31 ·
NCT07815665 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Regulatory and conference events (12) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
16 November 2026 Approval Gumokimab NMPA approves gumokimab in active ankylosing spondylitis 14 November 2026 FDA action date Ivonescimab Ivonescimab PDUFA goal action date (EGFRm NSCLC post-TKI) 5 November 2026 Priority review Ivonescimab NMPA grants priority review to ivonescimab plus chemotherapy in first-line biliary tract cancer 25 October 2026 Topline result Ivonescimab Phase 3 HARMONi-GI1 met its primary endpoint of overall survival 12 August 2026 Approval Ivonescimab NMPA approves ivonescimab plus chemotherapy in first-line squamous NSCLC June 2026 Presentation Ligufalimab Randomized Phase 2 AK117-206 at EHA 2026: median EFS 9.1 vs 6.9 months with ligufalimab added February 2026 Filing accepted Manfidokimab China's NMPA accepts Akeso's NDA for manfidokimab (AK120) in atopic dermatitis 29 January 2026 Filing accepted Ivonescimab FDA accepts Summit's BLA for ivonescimab plus chemotherapy (EGFRm NSCLC post-TKI) 19 January 2026 Filing accepted Gumokimab NMPA accepts the gumokimab supplemental NDA for active ankylosing spondylitis 25 August 2025 Topline result Manfidokimab Phase 3 topline: primary endpoints met 25 August 2025 Topline result Gumokimab AK111-303 (NCT06378697) Phase 3 in ankylosing spondylitis met its primary endpoint 7 November 2023 Topline result Cadonilimab AK104-302 (NCT05008783) Phase 3 met its primary endpoint Financial reports Annual history (1 year)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-FY $295M $166M $1.0B $72M report ↗